1. Home
  2. KRSA vs CMMB Comparison

KRSA vs CMMB Comparison

Compare KRSA & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KRSA

Korsana Biosciences Inc. Common Stock

N/A

Current Price

$33.93

Market Cap

23.4M

Sector

Health Care

ML Signal

N/A

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

HOLD

Current Price

$2.49

Market Cap

20.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRSA
CMMB
Founded
N/A
2004
Country
United States
Israel
Employees
N/A
12
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.4M
20.5M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
KRSA
CMMB
Price
$33.93
$2.49
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
N/A
122.5K
Earning Date
N/A
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
101.67
EPS
N/A
0.04
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$65.25
Revenue Growth
N/A
N/A
52 Week Low
N/A
$1.35
52 Week High
N/A
$3.55

Technical Indicators

Market Signals
Indicator
KRSA
CMMB
Relative Strength Index (RSI) N/A 52.46
Support Level N/A $1.47
Resistance Level N/A $2.92
Average True Range (ATR) 0.00 0.21
MACD 0.00 -0.04
Stochastic Oscillator 0.00 21.86

Price Performance

Historical Comparison
KRSA
CMMB

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Share on Social Networks: